Liver FailurePhase 2NCT00608244

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

A Phase 2 study testing LCP Tacro and Prograf in people with Liver Failure, run by Veloxis Pharmaceuticals at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules. Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Liver Failure
What is being tested?: LCP Tacro and Prograf
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 59 participants
Where: 1 siteUnited States
Study dates: Nov 2007to Jun 2008
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Men and women 18-65 years of age who are recipients of a liver transplant at least six months prior to enrollment
Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 5-12 ng/mL for at least four weeks prior to enrollment with at least two measurements at least two days apart in the screening period up to fourteen days prior to enrollment
Concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic) is allowed but patients on either of these medications should be on stable doses for at least four weeks prior to enrollment
Patients with stable serum bilirubin, AST, ALT, and Alk Phos or GGT that are ≤ 2 times the upper limit of normal based on local laboratory criteria
Patients with serum creatinine ≤2.0 mg/dL prior to enrollment
Able to swallow study medication
Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study protocol.
Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.

Who cannot join

Recipients of any transplanted organ other than a liver
White blood cell count ≤ 2.8 x 109/L
Patients who are receiving a total dose of Prograf < 3 mg per 24 hours
Patients who are receiving more than 10 mg of prednisone per day
Patients unable or unwilling to provide informed consent
Pregnant or nursing women

Show all 22Show fewer

Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception
Administration of any other investigational agent in the three months prior to enrollment
Patients receiving any drug interfering with tacrolimus metabolism
Patients who have taken sirolimus within the three months prior to screening
Patient with an episode of acute cellular requiring antibody therapy within the six months prior to enrollment
Patients treated for acute cellular rejection within the thirty days prior to enrollment
Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver
Patients presenting after liver transplantation with recurrent HCV infection, documented by presence of HCV RNA in serum and grade II or greater inflammation or stage II or greater fibrosis on liver biopsy
Patients being actively treated with antiviral therapy, such as interferons or ribavirin, for recurrent hepatitis C.
Patients with an alpha-feto protein ≥ 20 ng/mL
Patient has a current malignancy or a history of malignancy (within the past five years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
Patient has uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
Patient will require therapy with any immunosuppressive agent other than those prescribed in the study
Patient has a known hypersensitivity to corticosteroids or tacrolimus
Patient has any form of current substance abuse (patients must pass a standard drug screen), psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator Version

Trial locations and contacts

1 site in 1 country.

United States1 site

University of Cincinnati
Cincinnati, Ohio, 44123

Other trials in United States

About this study

Official title: A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day

Read the detailed description

Stable liver transplant patients who fulfill all I/E criteria will be enrolled and kept on Prograf for 7 days. Following a 24-hour PK study on Day 7 to determine pharmacokinetics for Prograf, all patients will be converted to once daily LCP-Tacro for 14 days with one fixed dose change allowed at Day 15.

On Day 14 and Day 21 a 24-hour LCP-Tacro PK study will be performed. On Day 22 patients will be converted back to their original twice daily dose of Prograf for a safety follow-up period of 30 days ending with a safety assessment on day 53.

Conditions: Liver Failure
Being tested: LCP Tacro, Prograf
Keywords: Tacrolimus, Pharmacokinetics, Liver Transplantation
Medical subject headings: Liver Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LCP TacroDrug
Also called tacrolimus
In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.
LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.
Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.
PrografDrug
Also called Tacrolimus
Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.

Study groups in NCT00608244
Study group	Role	What they receive
LCP-Tacro	Experimental	Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL. LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets. Receives: Drug: LCP Tacro; Drug: Prograf

What is being measured

The primary outcome is the main question the study is designed to answer.

Evaluation of Steady State Tacrolimus Trough Levels (C24).
Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.
Measured: 7 Days
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).
Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.
The following time points were used to obtain the PK curve for Prograf on day 7: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 16, 20 and 24 hours after the morning dose.
Measured: 7 Days
Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.
Measured: 21 Days
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24) on Day 21.
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).
The following time points were used to obtain the PK curve for LCP-Tacro on day 21: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20 and 24 hours post-dose.
Measured: 21 Days
Safety Evaluation
A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.
Measured: 52 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Nov 2007Jun 2008

First posted6 Feb 2008 (estimated)
Study startNov 2007
Primary completionJun 2008
Study completionJun 2008

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Liver FailureStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 59 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00608244
Sponsor's protocol ID: LCP Tacro 2012
Status last verified: Aug 2015
First submitted: 23 Jan 2008
Last updated: 28 Aug 2015
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Publications

Alloway RR, Eckhoff DE, Washburn WK, Teperman LW. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl. 2014 May;20(5):564-75. doi: 10.1002/lt.23844. Epub 2014 Mar 26.
PubMed 24493215

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
RecruitingObservational study
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Inherited Disease, Rare Diseases
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure

All Liver Failure trials

Study at a glance

From the registry record, last updated by the sponsor on 28 Aug 2015. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day
ClinicalTrials.gov ID: NCT00608244
Acronym / sponsor ID: LCP Tacro 2012
Conditions: Liver Failure
Keywords: Tacrolimus, Pharmacokinetics, Liver Transplantation
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 59 participants (actual)
Lead sponsor: Veloxis PharmaceuticalsIndustry (pharma, biotech, devices)
Collaborators: CTI Clinical Trial and Consulting Services
Study start: Nov 2007
Primary completion: Jun 2008 (actual)
Study completion: Jun 2008 (actual)
First posted: 6 Feb 2008 (estimated)
Results: Posted 28 Aug 2015

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
LCP-Tacro	Experimental	Drug: LCP Tacro, Drug: PrografPrograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL. LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (8 listed)

Men and women 18-65 years of age who are recipients of a liver transplant at least six months prior to enrollment
Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 5-12 ng/mL for at least four weeks prior to enrollment with at least two measurements at least two days apart in the screening period up to fourteen days prior to enrollment
Concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic) is allowed but patients on either of these medications should be on stable doses for at least four weeks prior to enrollment
Patients with stable serum bilirubin, AST, ALT, and Alk Phos or GGT that are ≤ 2 times the upper limit of normal based on local laboratory criteria
Patients with serum creatinine ≤2.0 mg/dL prior to enrollment

Key exclusion criteria (22 listed)

Recipients of any transplanted organ other than a liver
White blood cell count ≤ 2.8 x 109/L
Patients who are receiving a total dose of Prograf < 3 mg per 24 hours
Patients who are receiving more than 10 mg of prednisone per day
Patients unable or unwilling to provide informed consent

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LCP TacroAlso: tacrolimusIn the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8. LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.	Drug	LCP-Tacro
PrografAlso: TacrolimusPrograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.	Drug	LCP-Tacro

Primary outcome

Evaluation of Steady State Tacrolimus Trough Levels (C24).
Time frame: 7 Days
Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).
Time frame: 7 Days
Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro. The following time points were used to obtain the PK curve for Prograf on day 7: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 16, 20 and 24 hours after the morning dose.
Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).
Time frame: 21 Days
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24) on Day 21.
Time frame: 21 Days
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours). The following time points were used to obtain the PK curve for LCP-Tacro on day 21: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20 and 24 hours post-dose.
Safety Evaluation
Time frame: 52 days
A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.

Results and safety

Results posted to the registry on 28 Aug 2015, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
LCP-Tacro	59	57

Primary outcome: Evaluation of Steady State Tacrolimus Trough Levels (C24).

Time frame: 7 Days. Mean (Standard Deviation). Unit: ng/mL

Measure	Prograf n = 57
Value	6.72 (2.07)

Population analysed: The arithmetic mean and standard deviation is given.

Primary outcome: Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).

Time frame: 7 Days. Mean (Standard Deviation). Unit: ng*hr/mL

Measure	Prograf n = 57
Value	205.14 (61.0)

Population analysed: The arithmetic mean and standard deviation is given.

Primary outcome: Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).

Time frame: 21 Days. Mean (Standard Deviation). Unit: ng/mL

Measure	LCP-Tacro n = 56
Value	6.85 (2.63)

Population analysed: 57 completed the study but one patient was excluded from the PP analysis due to low trough levels. The arithmetic mean and standard deviation is given.

Primary outcome: Evaluation of Steady State Tacrolimus Exposure (AUC 0-24) on Day 21.

Time frame: 21 Days. Mean (Standard Deviation). Unit: ng*hr/mL

Measure	LCP-Tacro n = 56
Value	215.66 (79.40)

Population analysed: 57 completed the study but one patient was excluded from the PP analysis due to low trough levels. The arithmetic mean and standard deviation is given.

Adverse events

Time frame: Adverse events were collected from time of first dose of study drug and until the end of the follow up period at day 52.. Other adverse events reported at 2% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
LCP-Tacro	1 of 59 (1.7%)	19 of 59 (32.2%)	Not reported
Prograf	0 of 59 (0%)	7 of 59 (11.9%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2015.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 24493215Alloway RR, Eckhoff DE, Washburn WK, Teperman LW. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl. 2014 May;20(5):564-75. doi: 10.1002/lt.23844. Epub 2014 Mar 26.

Related trials for Liver Failure

Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
RecruitingObservational study
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Inherited Disease, Rare Diseases
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Rita Alloway, PharmD principal investigator

University of Cincinnati

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing LCP Tacro and Prograf in people with Liver Failure, run by Veloxis Pharmaceuticals at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Aug 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of Steady State Tacrolimus Trough Levels (C24). (time frame: 7 Days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00608244, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2015.